Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL
Patients were randomly assigned (1:1) to receive either 6 cycles of FCR every 28 days or IR for up to 6 years.
Patients were randomly assigned (1:1) to receive either 6 cycles of FCR every 28 days or IR for up to 6 years.
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Hypogammaglobulinemia often occurs in patients with chronic lymphocytic leukemia who receive CAR-T, but there is no standard way to manage it.
MRD-negativity is defined as <1 CLL cell per 10,000 lymphocytes detected in the blood or bone marrow using sensitive analytical models.